Several selective vulnerabilities to olaparib have been demonstrated in AML and ALL molecular subgroups, that will be better described in “Synthetic lethality and PARP inhibitors: a new therapeutic window for acute leukemia?” section. Here, PARP1 is linked to acute leukemia.